Nutex Health shareholders elect board, approve plan amendments at annual meeting

Nutex Health Inc. (NASDAQ:NUTX) reported Wednesday that shareholders approved all proposals presented at the company’s annual meeting held Monday.

According to a press release statement based on the company’s SEC filing, shareholders voted to elect seven directors to serve one-year terms expiring at the 2026 annual meeting. The elected directors are Thomas T. Vo, Warren Hosseinion, Cheryl Grenas, Michael L. Reed, Scott J. Saunders, Kelvin Spears, and Frank E. Jaumot.

Approximately 71% of the company’s outstanding common shares were represented at the meeting, with 3,916,269 shares voted out of 5,555,116 eligible shares.

Shareholders also approved, on an advisory basis, the compensation of Nutex Health’s named executive officers. The vote results were 2,556,545 shares in favor, 226,342 against, and 16,718 abstaining, with 1,116,664 broker non-votes.

Additionally, an amendment to the Nutex Health 2023 Equity Incentive Plan was approved. The amendment increases the number of shares available for issuance under the plan by 1,100,000 and allows for an automatic annual increase on January 1 equal to 5% of the outstanding shares at the end of the previous fiscal year, unless the board determines otherwise. The vote totals were 2,075,665 for, 723,697 against, and 243 abstentions, with 1,116,664 broker non-votes.

Grant Thornton LLP was ratified as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2025. The ratification received 3,833,735 votes in favor, 64,794 against, and 17,740 abstentions.

The information in this article is based on a press release statement and the company’s filing with the Securities and Exchange Commission. For deeper insights into Nutex Health’s financial health and growth prospects, including exclusive ProTips and comprehensive analysis, visit InvestingPro, where you’ll find detailed research reports and expert financial metrics.

In other recent news, Nutex Health Inc. has reported a substantial financial growth in its first-quarter earnings for 2025, with revenue reaching $211.8 million, marking a 214% increase year-over-year. This impressive revenue surge is largely attributed to successful outcomes in arbitration processes under the No Surprise Act, contributing approximately $105 million. The company has also seen a significant improvement in adjusted EBITDA, which rose to $72.8 million from a loss in the previous year. Nutex Health is on track to open three new hospitals in the second half of 2025, continuing its expansion plans. In corporate developments, the company has appointed Grant Thornton LLP as its new auditor for the fiscal year ending December 31, 2025. Benchmark has reiterated a Buy rating for Nutex Health, maintaining a price target of $300, reflecting confidence in the company’s continued strong performance. Additionally, Nutex Health’s chief operating officer, Joshua DeTillio, announced his resignation effective August 8, 2025, to pursue a CEO position elsewhere, prompting the company to begin a search for his replacement.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.